|
537
|
| 2736 |
PINK1
|
NOT |
affects_quantity of
|
SOD2
|
|
|
19270741
|
Parkinson disease
|
|
598
|
| 3215 |
high-phytoestrogen soy-based diet
|
|
increases_expression of
|
SOD2
|
|
|
18420492
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
787
|
| 4540 |
LPIN1
|
|
increases_expression of
|
SOD2
|
if LPIN1 is overexpressed
|
|
16950137
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
904
|
| 5396 |
SIRT1
|
|
affects_expression of
|
SOD2
|
on standard diet, on high-fat diet, if SIRT1 is overexpressed
|
|
18599449
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
1,012
|
| 6307 |
PARK7
|
|
increases_expression of
|
SOD2
|
|
| 6313 |
SOD2
|
|
decreases_quantity of
|
Reactive oxygen species
|
|
|
18689799
|
Parkinson disease
|
|
1,013
|
| 6317 |
PARK7-p.L166P
|
|
decreases_quantity of
|
SOD2
|
|
| 6318 |
PARK7-n.del-exon1-5
|
|
decreases_quantity of
|
SOD2
|
|
|
18689799
|
Parkinson disease
|
|
1,014
|
| 6319 |
PARK7
|
|
increases_quantity of
|
SOD2
|
|
| 6320 |
PARK7-p.M26I
|
NOT |
increases_quantity of
|
SOD2
|
|
|
18689799
|
Parkinson disease
|
|
1,016
|
| 6332 |
PPARGC1A
|
|
increases_expression of
|
SOD2
|
|
| 6341 |
SFPQ
|
|
decreases_expression of
|
SOD2
|
if expression has been activated by PGC-1alpha
|
|
18689799
|
Parkinson disease
|
|
1,442
|
| 10126 |
SOD2
|
|
decreases_quantity of
|
O2-
|
|
| 10135 |
SOD2
|
|
decreases_activity of
|
response to oxidative stress
|
|
| 10137 |
SOD2
|
|
affects_activity of
|
erythrocyte development
|
|
|
20800516
|
Parkinson disease
|
|
1,444
|
| 10143 |
SOD2
|
|
affects_expression of
|
PARK7
|
in erythroblasts
|
| 10148 |
SOD2
|
|
affects_activity of
|
protein oxidation
|
via an increase of ROS production
|
| 10150 |
SOD2
|
|
decreases_quantity of
|
Reactive oxygen species
|
|
| 10611 |
SOD2
|
|
decreases_activity of
|
response to oxidative stress
|
|
| 10794 |
SOD2
|
|
affects_activity of
|
erythrocyte development
|
|
|
20800516
|
Parkinson disease
|
|
1,497
|
| 10569 |
Parkinson disease
|
|
increases_expression of
|
SOD2
|
in frontal cortex
|
| 10571 |
Dementia, Lewy body
|
|
increases_expression of
|
SOD2
|
in frontal cortex
|
|
19298851
|
Dementia, Lewy body
Parkinson disease
|
|
1,592
|
| 11538 |
inflammatory response
|
|
increases_expression of
|
SOD2
|
|
| 11602 |
Genistein
|
|
decreases_expression of
|
SOD2
|
in inflamed cells
|
|
20816778
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,675
|
| 12480 |
SOD1-p.G93A
|
|
increases_quantity of
|
SOD2
|
in spinal cord mitochondria
|
|
21078990
|
Amyotrophic lateral sclerosis
|
|
1,722
|
| 12937 |
SOD2
|
|
decreases_activity of
|
SOD1-p.G37R
|
if SOD2 is overexpressed
|
| 12938 |
SOD2
|
|
decreases_activity of
|
SOD1-p.G93C
|
if SOD2 is overexpressed
|
| 12939 |
SOD2
|
|
decreases_activity of
|
SOD1-p.G85R
|
if SOD2 is overexpressed
|
| 12940 |
SOD2
|
|
decreases_activity of
|
SOD1-p.I113T
|
if SOD2 is overexpressed
|
| 12941 |
SOD2
|
|
decreases_activity of
|
neuron death
|
if SOD2 is overexpressed
|
| 12959 |
SOD2
|
|
decreases_quantity of
|
O2-
|
in mitochondria; if SOD2 is overexpressed in mutant SOD1 neural cells
|
|
17394531
|
Amyotrophic lateral sclerosis
|
|
1,850
|
| 14047 |
Obesity
|
|
increases_expression of
|
SOD2
|
in muscle
|
| 14070 |
Palmitic acid
|
|
increases_expression of
|
SOD2
|
in muscle; via NF-kappaB
|
|
18633101
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,858
|
| 14034 |
convulsive seizures
|
|
decreases_quantity of
|
SOD2
|
|
|
20446108
|
Epilepsy
|
|
1,863
|
| 14161 |
MT-TK-c.A8344G
|
|
increases_activity of
|
SOD2
|
|
|
20411357
|
MERRF
|
|
1,951
|
| 15095 |
convulsive seizures
|
|
decreases_expression of
|
SOD2
|
|
|
18816793
|
Epilepsy
Status epilepticus
|
|
2,083
|
| 16815 |
SOD2
|
NOT |
increases_quantity of
|
Reactive oxygen species
|
if SOD2 is overexpressed and if induced by hyperglycemia
|
|
10783895
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,114
|
| 28623 |
Alzheimer disease
|
NOT |
affects_activity of
|
SOD2
|
|
|
22072713
|
Alzheimer disease
|
|
4,534
|
| 45443 |
SOD2
|
|
affects_activity of
|
abnormal mitochondrial physiology
|
|
| 45469 |
SOD2
|
|
affects_activity of
|
Glaucoma, primary open angle
|
|
|
22138560
|
Diabetes mellitus, type II
Developmental
Insulin resistance
Glaucoma, primary open angle
|
|
4,795
|
| 47475 |
Choline
|
|
affects_activity of
|
SOD2
|
in PEMT-/- mice
|
|
23179947
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
4,938
|
| 48835 |
THY-Tau22 transgenic mouse
|
|
increases_expression of
|
SOD2
|
MnSOD is a NRF2 target gene.
|
| 48839 |
Caffeine
|
|
decreases_expression of
|
SOD2
|
in TAU mice; MnSOD is a NRF2 target gene.
|
|
24780254
|
Alzheimer disease
Tauopathy
|
|
5,036
|
| 49683 |
OLR1
|
NOT |
decreases_activity of
|
SOD2
|
|
|
20203069
|
Cardiovascular disease
Atherosclerosis
|
|
5,152
|
| 50431 |
Resveratrol
|
|
increases_quantity of
|
SOD2
|
in kidney; in db/db mice
|
|
23090186
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
5,175
|
| 50643 |
ovariectomy
|
|
decreases_expression of
|
SOD2
|
in brain, in endothelial cells; via decreased PPARGC1B
|
|
23093066
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,222
|
| 50940 |
Quercetin
|
|
increases_expression of
|
SOD2
|
|
|
22469840
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,233
|
| 50966 |
response to oxidative stress
|
|
increases_expression of
|
SOD2
|
|
| 50975 |
PPARGC1A
|
|
affects_expression of
|
SOD2
|
|
|
17055439
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,298
|
| 51856 |
PPARGC1A
|
|
affects_expression of
|
SOD2
|
in skeletal muscle
|
|
17932564
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,301
|
| 51982 |
PPARGC1A
|
|
increases_expression of
|
SOD2
|
in skeletal muscle
|
| 51984 |
aging
|
|
decreases_expression of
|
SOD2
|
in skeletal muscle
|
|
19918075
|
Diabetes mellitus, type II
Insulin resistance
|
CIDeRplus